Highlights from the ESC congress 2020, Prof M. Roffi, 6.10.20

1. Highlights from the ESC congress 2020
2. Conflicts of interest
3. ESC Congress : the largest cardiovascular congress in the world
3.1. Logistal / technological challenge
3.2. Live studio in Amsterdam
3.3. Live studio in Amsterdam - 2
3.4. Live studio in Amsterdam - 3
3.5. Reality
3.6. Virtual
3.7. Reality
3.8. Virtual
3.9. Reality
4. Format of a hotline late breaking trial presentation
5. Technical support in the studios in Amsterdam
6. Technical / logistical support at the Heart House
7. NEW - ESC Clinical Pratice Guidelines
8. Renal Failure
8.1. DAPA-CKD
8.2. DAPA-CKD Results
8.3. Take-home messages
9. Heart failure
9.1. EMPEROR-Reduced Trial (SGLT2- Inhibitor Empagliflozin in HFrEF)
9.2. EMPEROR-Reduced: Results
9.3. Take home messages: EMPEROR-Reduced
10. Cariomyopathies
10.1. EXPLORER-HCM (Mavacamten in hypertrophic obstructive cardiomyopathy)
10.2. EXPLORER-HCM: Results
10.3. Take home messages: EXPLORER-HCM
11. Coronary artery disease
11.1. LODOCO 2 - Protocol
11.2. LODOCO 2 - enrolled / randomized / close-out
11.3. Patient extremely well treated
11.4. Primary end point
11.5. Key secondary end point
11.6. Compared with the most successful cardiovascular live envent to date
11.6.1. Compared with the most successful cardiovascular live envent to date (2)
12. Who participated at the congress ? From where ?
13. Compares well with our best live event
14. ESC 2020 The Digital Experience my take on ESC 2020
15. No way back, not because of COVID - let's not forget them
16. Page blanche
16.1. LOCODO
16.2. ESC going digital
16.3. The ESC 2020 Digital Experience a tight schedule
16.4. A very different mix of nationalities from our usual congress audience
16.5. SGLT2 Inhibitors in HFrEF

FINISH

SUBMIT

Title

Title

Title